The opportunity to present original research, case series, and case reports to the Symposium for Inflammatory Skin Disease® attendees is an integral part of the conference’s continuing education program. Encore abstracts/posters are permitted. Posters will be available on the SISD website until December 31, 2021.
New feature: the top 3 posters will be selected for a 10-minute oral presentation (7-minute presentation immediately followed by 3 minutes of Q&A) scheduled for April 10, 2021 at4:00pm – 4:30pm.
Poster submission is a 2-step process:
All abstracts will be submitted electronically via the Symposium for Inflammatory Skin Disease® website. Send an abstract of the study by March 31, 2021, which will be reviewed and accepted based on scientific value and educational need. Abstracts may be submitted by dermatologists, dermatology residents, medical students and dermatology researchers at universities, medical schools, or industry. Please allow up to 1 week from date of submission for notification of approval or denial.
If approved, poster submissions of approved abstracts are electronically due on April 2, 2021.
Abstract Submission Rules & Guidelines Submission deadline: 11:59pm Pacific Time on Friday, March 31, 2021. After this date/time, the submissions site will close automatically and can no longer accept submissions. There will be no exceptions to this policy. Abstract submission fee: The fee is $400 per abstract (fellows/residents/students have special pricing at $45 per abstract. Please contact email@example.com). Each abstract must be submitted separately. There is no limit on the number of abstracts a company may submit. Payment is required upon submission of this form. The fee is non-refundable unless your abstract is not accepted, in which case you will receive a full refund. Format: Abstracts must be submitted as .pdf documents. File name: must include supporting company name and lead author’s last name. Margins: 1-inch top, bottom, left and right, single spaced; laser printer quality. Font: font size must be 12-point Times Roman. Length: 500 words maximum inclusive of title, author and affiliations. Abstracts should be a maximum of one 8.5” x 11” page.
Content: Abstracts should reflect content of the poster and must include the poster title. Abstracts should contain the following: a) introduction that states the purpose of the study; b) brief description of the procedure/study; c) brief description of the results; and d) conclusion. Tables/illustrations may not be included in abstracts.
Brand Names: Generic or scientific names of drugs/devices should be used in place of brand names. If brand name is necessary to understand poster content, it should be used only once (after the first mention of the drug or device’s name). Pharmaceutical or other support of any study should be acknowledged at the end of the abstract and at the end of the poster.
Copyright: Copyright is shared. The Dermatology Research and Education Foundation™ owns copyright for its own use. Author(s) retain the rights for all other uses.
Note: Pricing is available if interested in additional features such as uploading to the SISD website audio slides, audio files/commentaries, and author videos for presentations.
Content: Poster content should be organized into background, objective, methods, results, and conclusion. Inclusion of graphs, tables and other visual is strongly recommended to enhance engagement. Include all authors and affiliations. All authors must disclose financial relationships. One author is required to register for the conference. Either PDF or PPT format is acceptable, but if in PPT format, please limit to 10 slides total. Commercialism: Any display at the 2021 Symposium for Inflammatory Skin Disease® in which cost is underwritten by a pharmaceutical company or other entity must avoid commercialism. Drugs, instrumentation, or devices must not use brand names. If such situations occur, the author/exhibitor is responsible for identifying and clearly stating on the poster that a portion or portions of the cost were provided by the commercial company named.